Advances in the Diagnosis of Eye Diseases

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 437

Special Issue Editor


E-Mail Website
Guest Editor
Eye Clinic Zrenieto, 1000 Sofia, Bulgaria
Interests: ophthalmology; glaucoma; age-related macular degeneration

Special Issue Information

Dear Colleagues,

Eye diseases, such as cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy, continue to represent leading causes of vision impairment and blindness worldwide. Timely and accurate diagnosis is crucial in providing appropriate treatment and preventing irreversible vision loss. Hence, this Special Issue will highlight cutting-edge research, innovative technologies, and novel approaches that are improving the early detection, diagnosis, and monitoring of eye diseases.

We invite researchers to submit original research findings, review articles, and case studies that demonstrate advancements in diagnostic tools, imaging techniques, biomarkers, artificial intelligence applications, and other innovative approaches to the diagnosis of eye diseases.

Overall, the goal of this Special Issue is to provide a platform for sharing and disseminating the latest developments in the diagnosis of eye diseases, ultimately leading to improved patient outcomes and better management of eye health. We hope that this Special Issue will inspire further research and innovation in this critical area of ophthalmology.

Dr. Ivan Tanev
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cataracts
  • glaucoma
  • age-related macular degeneration
  • diabetic retinopathy
  • OCT
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1136 KiB  
Article
Baseline Choroidal Blood Flow Imbalance as a Predictive Factor for Macular Edema Recurrence Secondary to Branch Retinal Vein Occlusion
by Ryuya Hashimoto, Kenichiro Aso, Keisuke Yata, Naoki Fujioka, Kazufumi Tanaka, Serika Moriyama, Asato Hirota, Juri Kawamura and Takatoshi Maeno
Diagnostics 2024, 14(20), 2328; https://doi.org/10.3390/diagnostics14202328 (registering DOI) - 18 Oct 2024
Viewed by 217
Abstract
Background/Objectives: To evaluate the roles of choroidal blood flow (CBF) and choroidal thickness (CT) as predictors of macular edema recurrence in patients with treatment-naive non-ischemic branch retinal vein occlusion (BRVO) after intravitreal ranibizumab (IVR) injection. Methods: Sixteen eyes from sixteen patients with treatment-naive [...] Read more.
Background/Objectives: To evaluate the roles of choroidal blood flow (CBF) and choroidal thickness (CT) as predictors of macular edema recurrence in patients with treatment-naive non-ischemic branch retinal vein occlusion (BRVO) after intravitreal ranibizumab (IVR) injection. Methods: Sixteen eyes from sixteen patients with treatment-naive non-ischemic BRVO treated with IVR, once initially and then as needed, were included in the study. CBF and CT in the subfovea, occlusive, and non-occlusive regions were measured via laser speckle flowgraphy and enhanced depth imaging optical coherence tomography over 12 months. Results: Baseline CT was significantly greater in the occlusive region (335 ± 72.1 µm) than in the non-occlusive region (274 ± 36.7 µm, p = 0.028). CT in the occlusive region was reduced significantly after 1 week (p = 0.008), but CBF did not change significantly after IVR throughout the follow-up period (p > 0.05). The occlusive/non-occlusive region CBF ratio at baseline was significantly associated with the number of IVR injections over 12 months (mean 2.63) in patients with BRVO (p = 0.048). Conclusions: Baseline CBF imbalance in eyes with treatment-naive BRVO may indicate the recurrence of macular edema after ranibizumab therapy. Full article
(This article belongs to the Special Issue Advances in the Diagnosis of Eye Diseases)
Back to TopTop